DDInter1860 DDInter1652
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Triazolam {u} (Compound) resembles {v} (Compound) Camazepam
Triazolam {u} (Compound) resembles {v} (Compound) Brotizolam
Triazolam {u} (Compound) binds {v} (Gene) GABRA3
Triazolam {u} (Compound) is included by {v} (Pharmacologic Class) Benzodiazepines
Triazolam {u} (Compound) causes {v} (Side Effect) Anterograde amnesia
Triazolam (Compound) resembles Camazepam (Compound)
Triazolam (Compound) resembles Brotizolam (Compound)
Triazolam (Compound) binds GABRA3 (Gene)
Triazolam (Compound) is included by Benzodiazepines (Pharmacologic Class)
Triazolam (Compound) causes Anterograde amnesia (Side Effect)